Symbol="IVVD"
AssetType="Common Stock"
Name="Invivyd Inc."
Description="Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, is focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases in the United States. The company is headquartered in Waltham, Massachusetts."
CIK="1832038"
Exchange="NASDAQ"
Currency="USD"
Country="USA"
Sector="LIFE SCIENCES"
Industry="BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)"
Address="303 WYMAN STREET, SUITE 300, WALTHAM, MA, US"
FiscalYearEnd="December"
LatestQuarter="2023-03-31"
MarketCapitalization="159844000"
EBITDA="-163608000"
PERatio="None"
PEGRatio="None"
BookValue="2.989"
DividendPerShare="0"
DividendYield="0"
EPS="-1.57"
RevenuePerShareTTM="0"
ProfitMargin="0"
OperatingMarginTTM="0"
ReturnOnAssetsTTM="-0.226"
ReturnOnEquityTTM="-0.448"
RevenueTTM="0"
GrossProfitTTM="0"
DilutedEPSTTM="-1.57"
QuarterlyEarningsGrowthYOY="0"
QuarterlyRevenueGrowthYOY="0"
AnalystTargetPrice="2.5"
TrailingPE="-"
ForwardPE="-"
PriceToSalesRatioTTM="-"
PriceToBookRatio="0.499"
EVToRevenue="-"
EVToEBITDA="0.821"
Beta="None"
num_52WeekHigh="4.9"
num_52WeekLow="0.98"
num_50DayMovingAverage="1.339"
num_200DayMovingAverage="1.913"
SharesOutstanding="109482000"
DividendDate="None"
ExDividendDate="None"
symbol="IVVD"
open="1.49"
high="1.51"
low="1.35"
price="1.40"
volume="203142.00"
latest_trading_day="2023-07-24"
previous_close="1.46"
change="-0.06"
change_percent="-4.1096%"
aroon_positive_momentum_days="0"
aroon_negative_momentum_days="72"
trend_strength="Absent or Weak Trend"
buying_signal="Weak Sell Signal"
volume_analysis="Target Volume"
value_analysis="Expected Range"
Aroon_change="FALSE"
Aroon_momentum="28"
Volume_recent_avg="319094"
Change_recent_avg="-0.01"
Delta_recent_avg="0.14"
Variance_recent_avg="0.07"
Change_ratio_recent_avg="-0.66"
RSI_change="FALSE"
ADX_change="FALSE"

event="FALSE"
Aroon_signal="negative"
Aroon_change="FALSE"
Aroon_momentum_positive="28"
Aroon_momentum_negative="72"
image_negative_thumbnail_id_1="175"
image_negative_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/05/MI_Finance_Negative_Landscape_0001.jpeg"
image_negative_thumbnail_id_2="134"
image_negative_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/05/MI_Finance_Negative_Landscape_0042.jpeg"
image_neutral_thumbnail_id_1="533"
image_neutral_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0066.jpeg"
image_neutral_thumbnail_id_2="595"
image_neutral_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0004.jpeg"
image_positive_thumbnail_id_1="630"
image_positive_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0078.jpeg"
image_positive_thumbnail_id_2="1000"
image_positive_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0162.jpeg"
image_professor_thumbnail_id_1="1199"
image_professor_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0033.jpeg"
image_professor_thumbnail_id_2="1183"
image_professor_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0017.jpeg"
